Evidence map›Paper›PMID 41064595›Full record

ArticleNAR genomics and bioinformatics2025

VIRUS-MVP: a framework for comprehensive surveillance of viral mutations and their functional impacts.

Muhammad Zohaib Anwar, Ivan S Gill, Madeline Iseminger, Anoosha Sehar, Emma J Griffiths, Damion Dooley, Jun Duan, Khushi Vora, Gary Van Domselaar, Fiona S L Brinkman and 2 more

Abstract read
In one paragraph

Article in NAR genomics and bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Muhammad Zohaib AnwarCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.ORCID https://orcid.org/0000-0001-8236-485X
Ivan S GillCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.
Madeline IsemingerCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.ORCID https://orcid.org/0000-0002-0548-891X
Anoosha SeharCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.ORCID https://orcid.org/0000-0001-5275-8866
Emma J GriffithsCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.ORCID https://orcid.org/0000-0002-1107-9135
Damion DooleyCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.ORCID https://orcid.org/0000-0002-8844-9165
Jun DuanCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.ORCID https://orcid.org/0000-0003-2279-9290
Khushi VoraCentre for Health Genomics and Informatics, Cumming School of Medicine, University of Calgary, Calgary, T2N 1N4 AB, Canada.
Gary Van DomselaarNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, R3E 3R2 MB, Canada.ORCID https://orcid.org/0000-0003-1139-4458
Fiona S L BrinkmanDepartment of Molecular Biology and Biochemistry, Simon Fraser University, V5A 1S6 Burnaby, Canada.ORCID https://orcid.org/0000-0002-0584-4099
Paul M K GordonCentre for Health Genomics and Informatics, Cumming School of Medicine, University of Calgary, Calgary, T2N 1N4 AB, Canada.ORCID https://orcid.org/0000-0003-2881-1713
William W L HsiaoCentre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6 BC, Canada.ORCID https://orcid.org/0000-0002-1342-4043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As viruses evolve, they accumulate genetic mutations that can influence disease severity, transmissibility, and the effectiveness of vaccines and therapeutics. Real-time tracking of viral mutations and their functional impacts is essential to understand these changes and assess their implications for public health responses. VIRUS-MVP is an interactive, portable platform designed for the comprehensive surveillance of viral mutations. Initially developed for SARS-CoV-2, it now fully supports mpox and is expanding to include influenza and RSV. The platform links viral mutations to functional annotations, providing insights into their predicted effects on viral infectivity, immune evasion, and protein functionality. It features an interactive interface for visualizing mutation distributions, a modular and reproducible genomics workflow, and a curated annotation resource that captures known impacts on viral proteins and host interactions. Users can also import custom functional annotations to tailor analyses to specific research needs or emerging pathogens. Developed collaboratively with public health and academic partners, VIRUS-MVP enhances understanding of viral evolution and its public health impact by bridging genomic data with biological insights. The platform is open-source, adaptable, and accessible on GitHub.

Indexed as

MutationSARS-CoV-2SoftwareCOVID-19Genome, ViralGenomicsHumansViral ProteinsViral Proteins

Identifiers

PMID41064595
PMCPMC12501772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.